Genfit S.A.
Research Genfit S.A. (GNFT) on Bullrun: market cap EUR 720.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGNFT
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 720.38M
- Financial periodFY2025
- RevenueEUR 65.43M
- Revenue growth-2.3%
- Net income-EUR 85.97M
- Free cash flow-EUR 29.66M
- Gross margin99.5%
Valuation Snapshot
latest market cap is EUR 720.38M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 65.43M | -EUR 85.97M | -EUR 29.66M | 99.5% | n/a | EUR 101.09M | EUR 150.69M | -EUR 22.54M |
| FY2024 | EUR 67.00M | EUR 1.51M | EUR 14.57M | 99.6% | 0.03 | EUR 81.79M | EUR 62.13M | EUR 69.22M |
| FY2023 | EUR 28.57M | -EUR 28.89M | -EUR 57.92M | 98.8% | -0.58 | EUR 77.79M | EUR 70.18M | EUR 67.95M |
| FY2022 | EUR 20.20M | -EUR 23.72M | -EUR 72.64M | 98.8% | -0.48 | EUR 136.00M | EUR 75.28M | EUR 94.53M |
| FY2021 | EUR 85.58M | EUR 67.26M | EUR 99.38M | n/a | 1.23 | EUR 258.76M | EUR 47.68M | EUR 119.10M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 720.38M | n/a | n/a | n/a |
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genfit S.A.'s market cap?
Genfit S.A.'s market capitalization is EUR 720.38M.
What does Genfit S.A. do?
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis.